|Last Price||Today's Change||52-Week Range||Trading Volume|
|33.24||0.15 (+0.45%)||27.51 - 36.46||20.4 million (Below Avg)|
Market data as of 4:01PM 10/09/15. Quotes are delayed by at least 15 min.
Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents
10/09/2015 1:45 PM ET
Pfizer Inc. Announces Final Results of Exchange Offers
10/02/2015 8:30 AM ET